Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.

摘要: Radionuclide therapy extends the usefulness of radiation from localized disease multifocal by combining radionuclides with disease-seeking drugs, such as antibodies or custom-designed synthetic agents. Like conventional radiotherapy, effectiveness targeted is ultimately limited amount undesired given to a critical, dose-limiting normal tissue, most often bone marrow. Because radionuclide relies on biological delivery radiation, its optimization and characterization are necessarily different than for therapy. However, principals radiobiology absorbed dose remain important predicting effects. Fortunately, emit gamma rays that allow measurement isotope concentrations in both tumor tissues body. By administering small "test dose" intended therapeutic drug, clinician can predict distribution patient. This serve basis effectiveness, optimize drug selection, select appropriate dose, order provide safest, effective treatment each Although planning individual patients based upon tracer dosimetry an attractive concept opportunity, practical considerations may dictate simpler solutions under some circumstances. There agreement (radiation distribution, cGy) should be utilized establish safety specific during development, but it less generally accepted used determine (radioactivity, GBq) administered patient (i.e., dose-based therapy). always tool developing assessing clinical results, establishing drug. Bone marrow continues "work progress." Blood-derived and/or body-derived acceptable conditions clearly do not account skeletal targeting radionuclide. Marrow expected improve significantly no method seems likely decreased reserve.